Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Dactinomycin; Irinotecan; Vincristine
- Indications Rhabdomyosarcoma
- Focus Pharmacogenomic; Therapeutic Use
- 27 Oct 2020 Biomarkers information updated
- 19 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2012 New source identified and integrated: Mayo Clinic